Neok Bio Emerges with $75M to Develop Dual-Targeting ADCs for Cancer Treatment
核心洞察
Neok Bio (搜索) launched with $75 million in Series A funding to develop bispecific antibody-drug conjugates that simultaneously target two distinct cancer proteins.
The company's lead programs Neok001 (搜索) and Neok002 (搜索) target B7-H3 (搜索)/ROR1 and EGFR (搜索)/MUC1 (搜索) protein pairs respectively, aiming to enhance efficacy and safety over conventional ADCs.
Both programs are expected to enter human testing in 2026 with results anticipated in 2027, backed by Korean antibody specialist ABL Bio (搜索).
Neok Bio (搜索) emerged from stealth mode with $75 million in Series A funding to develop what the company describes as "differentiated" antibody-drug conjugates (ADCs) designed to overcome limitations of existing cancer therapies. The biotechnology startup plans to advance dual-targeting ADCs that simultaneously bind to two distinct cancer targets, potentially improving therapeutic outcomes through enhanced specificity.
Dual-Targeting Strategy Addresses ADC Limitations
The company's approach focuses on developing bispecific ADCs that target "unique pairs" of cancer markers, moving beyond the single-target focus of conventional ADC therapies. According to CEO Mayank Gandhi, first-generation ADCs have a limited "therapeutic window" and the "majority" of injected doses don't reach tumors, causing effectiveness issues and side effects.
Neok's dual-targeting ADCs are designed to address a wider array of solid tumors with greater precision. "We feel like we'll be able to overcome these limitations and have more stable, homogeneous ADCs," Gandhi stated.
Lead Programs Target Well-Studied Cancer Proteins
The company has disclosed two lead programs in development. Neok001 (搜索) targets B7-H3 (搜索) and ROR1, two well-studied proteins involved in tumor growth, while Neok002 (搜索) focuses on cells expressing EGFR (搜索) and MUC1 (搜索). Both programs have demonstrated potential for "enhanced efficacy and safety" over typical ADCs across various tumor types, according to the company.
The financing will support advancing both lead programs into human testing next year, with results expected in 2027. Gandhi indicated the company "should be able to effectively target many indications with large unmet needs," including thoracic, gastrointestinal and gynecological tumors.
Strategic Partnership and Technology Platform
Neok's principal investor is ABL Bio (搜索), a Korean antibody engineering specialist with an established track record in bispecific antibodies for cancer and neurological diseases. ABL Bio has brought multiple bispecific antibodies into human testing and maintains partnerships with pharmaceutical companies including GSK and Sanofi.
"There's a great track record, and this is where their expertise to fine-tune and create these bispecific antibody constructs is very helpful," Gandhi explained.
The company's ADCs utilize linker technology developed by Synaffix, which was acquired by Lonza in 2023. This technology has been licensed to several biotechnology companies and is becoming established as a top-tier linker payload platform from a manufacturing perspective, according to Gandhi.
Competitive Landscape and Market Position
Neok enters a competitive field where large pharmaceutical companies including Pfizer and AstraZeneca are also advancing bispecific ADCs. The company is counting on its particular target pairings and ABL Bio (搜索)'s expertise to differentiate its approach in the crowded ADC development space.
The ADC market has become a hot spot for research and investment, with multiple approved medicines emerging in recent years. However, the technology remains imperfect, creating opportunities for startups with novel approaches to the precision chemotherapy concept.